


EMLc
ATC codes: **P01CB01**

<b>Indication</b>	Cutaneous leishmaniasis <span>ICD11 code: <b>1F54.1</b></span>
<b>Medicine type</b>	Chemical agent
<b>List type</b>	Core (EML) (EMLc)
<b>Formulations</b>	Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
<b>EML status history</b>	First added in 1987 ( <a href="#">TRS 770</a> ) Changed in 1989 ( <a href="#">TRS 796</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
<b>Sex</b>	All
<b>Age</b>	Also recommended for children
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .
<b>Wikipedia</b>	<a href="#">Meglumine antimoniate</a>
<b>DrugBank</b>	<a href="#">Meglumine antimoniate (Pentavalent Antimony)</a>

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule

